A new trading day began on Monday, with Esperion Therapeutics Inc (NASDAQ: ESPR) stock price up 0.09% from the previous day of trading, before settling in for the closing price of $0.80. ESPR’s price has ranged from $0.73 to $3.94 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 44.77%. Meanwhile, its annual earnings per share averaged 40.18%. With a float of $194.72 million, this company’s outstanding shares have now reached $196.66 million.
Considering the fact that the conglomerate employs 304 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 79.35%, operating margin of 16.37%, and the pretax margin is -15.57%.
Esperion Therapeutics Inc (ESPR) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc is 1.76%, while institutional ownership is 57.14%. The most recent insider transaction that took place on Apr 17 ’25, was worth 106. In this transaction Chief Commercial Officer of this company sold 108 shares at a rate of $0.98, taking the stock ownership to the 370,218 shares. Before that another transaction happened on Apr 17 ’25, when Company’s Chief Financial Officer sold 8 for $0.96, making the entire transaction worth $8. This insider now owns 481,702 shares in total.
Esperion Therapeutics Inc (ESPR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.18% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Here are Esperion Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Compared to the last year’s volume of 4.86 million, its volume of 8.94 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 19.02%. Additionally, its Average True Range was 0.11.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 3.80%, which indicates a significant decrease from 18.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.98% in the past 14 days, which was higher than the 73.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2602, while its 200-day Moving Average is $1.8849. Nevertheless, the first resistance level for the watch stands at $0.8491 in the near term. At $0.8994, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9389. If the price goes on to break the first support level at $0.7593, it is likely to go to the next support level at $0.7198. Should the price break the second support level, the third support level stands at $0.6695.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
With a market capitalization of 158.30 million, the company has a total of 198,149K Shares Outstanding. Currently, annual sales are 332,310 K while annual income is -51,750 K. The company’s previous quarter sales were 69,110 K while its latest quarter income was -21,320 K.
